Pfenex to Announce Third Quarter 2019 Financial Results on November 7th
October 24 2019 - 4:30PM
Pfenex Inc. (NYSE American: PFNX), a development and licensing
biotechnology company focused on leveraging its Pfēnex Expression
Technology® to develop and improve protein therapies for unmet
patient needs, announced today that it will report its financial
results for the third quarter 2019, after the market close on
Thursday, November 7, 2019.
The Company will host a conference call to discuss financial
results and general business updates at 4:30 PM Eastern Time on
Thursday, November 7, 2019.
Conference Call & WebcastThursday,
November 7th @ 4:30pm Eastern Time/1:30pm Pacific
TimeDomestic: 866-376-8058International:
412-542-4131Webcast:
https://www.webcaster4.com/Webcast/Page/1061/32120
Replays available through November 14th:Domestic:
877-344-7529International: 412-317-0088Replay Access Code:
10136405
About Pfenex Inc.
Pfenex is a development and licensing biotechnology company
focused on leveraging its Pfēnex Expression Technology® to develop
and improve protein therapies for unmet patient needs. Using the
patented Pfēnex Expression Technology platform, Pfenex has created
an advanced pipeline of potential therapeutic equivalents,
vaccines, biologics and biosimilars. Pfenex’s lead product
candidate is PF708, a therapeutic equivalent candidate to Forteo®
(teriparatide injection). PF708 has been approved in the U.S. for
the treatment of osteoporosis in certain patients at high risk of
fracture, and marketing authorization applications are pending in
other jurisdictions. In addition, Pfenex is developing
hematology/oncology products in collaboration with Jazz
Pharmaceuticals, including PF743, a recombinant crisantaspase, and
PF745, a recombinant crisantaspase with half-life extension
technology. Pfenex also uses its Pfēnex Expression Technology
platform to produce CRM197, a diphtheria toxoid carrier protein
used in prophylactic and therapeutic vaccines.
Pfenex investors and others should note that Pfenex announces
material information to the public about Pfenex through a variety
of means, including its website (http://www.pfenex.com/), its
investor relations website (http://pfenex.investorroom.com/), press
releases, SEC filings, public conference calls, corporate Twitter
account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with its disclosure
obligations under Regulation FD. Pfenex encourages its investors
and others to monitor and review the information Pfenex makes
public in these locations as such information could be deemed to be
material information. Please note that this list may be updated
from time to time.
Company Contact:Susan A. KnudsonChief Financial
Officer(858) 352-4324sknudson@pfenex.com
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Apr 2023 to Apr 2024